MEDICATION USE AMONG T2DM PATIENTS INITIATING TREATMENT WITH ONCE WEEKLY (OW) SEMAGLUTIDE

被引：0
|
作者：
Frazer, M. [1 ]
Swift, C. [2 ]
Sargent, A. [3 ]
Leszko, M. [3 ]
Buysman, E. K. [3 ]
Alvarez, S. [4 ]
Noone, J. [2 ]
Gamble, C. [2 ]
机构：
[1] Qual Metr, Johnston, RI USA
[2] Novo Nordisk Inc, Plainsboro, NJ USA
[3] Optum, Eden Prairie, MN USA
[4] Novo Nordisk Inc, Tacoma, WA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HSD49
引用
收藏
页码：S246 / S246
页数：1
相关论文
共 50 条
  • [1] MEDICATION UTILIZATION PATTERNS AMONG T2DM PATIENTS INITIATING TREATMENT WITH ORAL SEMAGLUTIDE
    Frazer, M.
    Swift, C.
    Sargent, A.
    Leszko, M.
    Buysman, E. K.
    Alvarez, S.
    Noone, J.
    Guevarra, M.
    VALUE IN HEALTH, 2023, 26 (06) : S255 - S255
  • [2] Real-World A1C Changes and Prescribing Provider Types among T2DM Patients Initiating Treatment with Once-Weekly (OW) Semaglutide
    Frazer, Monica S.
    Swift, Caroline
    Sargent, Andrew
    Leszko, Michael
    Buysman, Erin
    Alvarez, Sara B.
    Noone, Joshua
    Gamble, Cory L.
    DIABETES, 2022, 71
  • [3] Evaluating Antidiabetic Medication Treatment Patterns in T2D Patients Initiating Once-Weekly Semaglutide (sema OW)
    Willey, Vincent
    Shivappa, Nitin
    Swift, Caroline
    Noone, Joshua
    Du, Simo
    Paprocki, Yurek M.
    Tan, Hiangkiat
    DIABETES, 2021, 70
  • [4] CLINICAL EXPERIENCES OF TYPE 2 DIABETES (T2DM) PATIENTS INITIATING ORAL SEMAGLUTIDE
    Dunn, T. J.
    Swift, C.
    Guesnier, A.
    Noone, J.
    Willey, V
    VALUE IN HEALTH, 2022, 25 (07) : S309 - S309
  • [5] Efficacy by Baseline BMI with Once Weekly Dulaglutide in Chinese T2DM Patients
    Shi, Yongquan
    Zhang, Bin
    Wu, Haiya
    DIABETES, 2019, 68
  • [6] CHANGES IN DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES (T2DM) INITIATING SUBCUTANEOUS SEMAGLUTIDE
    Dunn, T. J.
    Swift, C.
    Guesnier, A.
    Noone, J.
    Willey, V
    VALUE IN HEALTH, 2022, 25 (07) : S321 - S321
  • [7] Real-World A1C Changes and Prescribing Provider Types among T2DM Patients Initiating Treatment with Oral Semaglutide
    Frazer, Monica S.
    Swift, Caroline
    Leszko, Michael
    Sargent, Andrew
    Buysman, Erin
    Alvarez, Sara B.
    Noone, Joshua
    Guevarra, Mico
    DIABETES, 2022, 71
  • [8] Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for Diabetes ☆
    Swift, Caroline
    Frazer, Monica
    Sargent, Andrew
    Leszko, Michael
    Buysman, Erin
    Gronroos, Noelle N.
    Alvarez, Sara
    Dunn, Tyler J.
    Noone, Josh
    CLINICAL THERAPEUTICS, 2025, 47 (04) : 277 - 283
  • [9] Real-World Evaluation of Once Weekly Semaglutide (Serra OW) in Patients Newly Initiating GLP-1 Agonist Therapy
    Shivappa, Nitin
    Swift, Caroline
    Noone, Joshua
    Du, Simo
    Paprocki, Yurek M.
    Tan, Hiangkiat
    Willey, Vincent
    DIABETES, 2021, 70
  • [10] Two-Year Use of Exenatide Once Weekly in Type 2 Diabetes Mellitus (T2DM) Patients Taking Thiazolidinedione
    Trautmann, Michael
    Norwood, Paul
    Pintilei, Ella
    Liutkus, Joanne
    Haber, Harry
    Boardman, Marilyn
    DIABETES, 2012, 61 : A293 - A293
12345